{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:00:54Z","timestamp":1781193654237,"version":"3.54.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G-1805"],"award-info":[{"award-number":["G-1805"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neuropharm.2025.110786","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:59:05Z","timestamp":1764172745000},"page":"110786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inhibition of levodopa-induced abnormal involuntary movements (AIMs) using a selective \u03b17 nicotinic positive allosteric modulator"],"prefix":"10.1016","volume":"284","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-646X","authenticated-orcid":false,"given":"Yasaman","family":"Malekizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Hassankhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice E.","family":"Kingslake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-1650","authenticated-orcid":false,"given":"Lucy E.","family":"Annett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Shoaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-9682","authenticated-orcid":false,"given":"Mahmoud M.","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110786_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17582024.2025.2528557","article-title":"Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases","volume":"15","author":"Al-Kassmy","year":"2025","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.neuropharm.2025.110786_bib2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/bs.pbr.2022.01.011","article-title":"Cholinergic systems, attentional-motor integration, and cognitive control in parkinson's disease","volume":"269","author":"Albin","year":"2022","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110786_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1155\/2004\/516302","article-title":"Parkinson's disease protects against smoking?","volume":"15","author":"Allam","year":"2004","journal-title":"Behav. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/ejn.14048","article-title":"Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias","volume":"49","author":"Bordia","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","article-title":"Continuous and intermittent nicotine treatment reduces L-3,4- dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease","volume":"327","author":"Bordia","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110786_bib6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.109.162396","article-title":"Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias May occur via desensitization","volume":"333","author":"Bordia","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110786_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.expneurol.2014.09.015","article-title":"The \u03b17 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions","volume":"263","author":"Bordia","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neuroscience.2013.09.047","article-title":"Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180711 evoke rapid and transient increases in prefrontal glutamate release","volume":"255","author":"Bortz","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110786_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105044","article-title":"Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats","volume":"144","author":"Brugnoli","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110786_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuroscience.2009.12.032","article-title":"Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats","volume":"166","author":"Buck","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110786_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuropharm.2012.10.019","article-title":"Positive allosteric modulator of alpha 7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human Primates","volume":"67","author":"Callahan","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110786_bib14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.neuint.2010.03.010","article-title":"In vivo modulation of \u03b17 nicotinic receptors on striatal glutamate release induced by anatoxin-A","volume":"56","author":"Campos","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2025.110786_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of L\u2010DOPA\u2010Induced dyskinesia in the unilateral 6\u2010OHDA lesion model of parkinson's disease in rats and mice","volume":"41","author":"Cenci","year":"2007","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuroscience.2019.04.008","article-title":"Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the hemi-parkinsonian rat","volume":"409","author":"Chambers","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110786_bib18","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1523\/JNEUROSCI.23-21-07820.2003","article-title":"Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice","volume":"23","author":"Champtiaux","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neubiorev.2018.05.021","article-title":"A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia","volume":"92","author":"Conti","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2025.110786_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pneurobio.2016.01.002","article-title":"Positive modulators of the \u03b17 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease","volume":"144","author":"Echeverria","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib24","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.22341","article-title":"The unified dyskinesia rating scale: presentation and clinimetric profile","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110786_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177655","article-title":"A positive allosteric modulator of \u03b17 nicotinic receptor reduces levodopa-induced dyskinesias in hemi-parkinsonian mice","volume":"998","author":"G\u00f3mez-Paz","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112776","article-title":"The \u03b17 nAChR allosteric modulator PNU-120596 amends neuroinflammatory and motor consequences of parkinsonism in rats: role of JAK2\/NF-\u03baB\/GSk3\u03b2\/TNF-\u03b1 pathway","volume":"148","author":"Gowayed","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2025.110786_bib27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bcp.2007.07.032","article-title":"The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum","volume":"74","author":"Grady","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/mol.107.035410","article-title":"Distinct profiles of \u03b17 nAChR positive allosteric modulation revealed by structurally diverse chemotypes","volume":"72","author":"Gr\u00f8nlien","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib31","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/brain\/awv096","article-title":"Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans","volume":"138","author":"Herz","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110786_bib32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1471-4159.2009.06011.x","article-title":"Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys","volume":"109","author":"Huang","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110786_bib33","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1523\/JNEUROSCI.5269-04.2005","article-title":"A novel positive allosteric modulator of the \u03b17 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization","volume":"25","author":"Hurst","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib34","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00702-011-0698-2","article-title":"Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation","volume":"118","author":"Iravani","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2025.110786_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.tips.2018.01.002","article-title":"Beyond the channel: metabotropic signaling by nicotinic receptors","volume":"39","author":"Kabbani","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/mol.117.111401","article-title":"Ionotropic and metabotropic mechanisms of allosteric modulation of \u03b17 nicotinic receptor intracellular calcium","volume":"93","author":"King","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123255","article-title":"Decrease of KATP channel expression through D3 receptor-mediated GSK3\u03b2 signaling alleviates levodopa-induced dyskinesia (LID) in parkinson's disease mouse mode","volume":"359","author":"Kuo","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib41","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bcp.2009.06.004","article-title":"Nicotinic acetylcholine receptors and the ascending dopamine pathways","volume":"78","author":"Livingstone","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1460-9568.2009.06613.x","article-title":"\u03917 and Non-\u03917 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex","volume":"29","author":"Livingstone","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib44","article-title":"Alpha7 nicotinic receptor- mediated reduction of L-DOPA-induced dyskinesia in 6-OHDA rat model of Parkinson's disease","author":"Malekizadeh","year":"2023","journal-title":"Brain Neurosci"},{"key":"10.1016\/j.neuropharm.2025.110786_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.75829","article-title":"A tonic nicotinic brake controls spike timing in striatal spiny projection neurons","volume":"11","author":"Matityahu","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.neuropharm.2025.110786_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/exnr.2002.7900","article-title":"Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats","volume":"175","author":"Meshul","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib49","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110786_bib50","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/pharmrev.120.000097","article-title":"Therapeutic targeting of \u03b1 7 nicotinic acetylcholine receptors","volume":"73","author":"Papke","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2025.110786_bib51","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/bph.13851","article-title":"Persistent activation of \u03b17 nicotinic ACh receptors associated with stable induction of different desensitized states","volume":"175","author":"Papke","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106736","article-title":"Silent agonists for \u03b17 nicotinic acetylcholine receptors","volume":"190","author":"Papke","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2025.110786_bib53","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/mds.26955","article-title":"Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice","volume":"32","author":"Perez","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110786_bib55","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pneurobio.2007.12.005","article-title":"It is not \u2018either\/or\u2019: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood","volume":"84","author":"Picciotto","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib58","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1471-4159.2006.04078.x","article-title":"Chronic oral nicotine treatment protects against striatal degeneration in MPTP-Treated Primates","volume":"98","author":"Quik","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110786_bib59","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib60","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mds.25594","article-title":"Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"28","author":"Quik","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110786_bib61","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bcp.2013.06.027","article-title":"Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice","volume":"86","author":"Quik","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-15161-7","article-title":"Behavioral changes after nicotine challenge are associated with \u03b17 nicotinic acetylcholine receptor-stimulated glutamate release in the rat dorsal striatum","volume":"7","author":"Ryu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110786_bib64","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neuint.2015.08.008","article-title":"Nicotinic receptors modulate the function of presynaptic AMPA receptors on glutamatergic nerve terminals in the trigeminal caudal nucleus","volume":"90","author":"Samengo","year":"2015","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2025.110786_bib67","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.neuron.2015.10.039","article-title":"M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-Induced dyskinesia","volume":"88","author":"Shen","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2025.110786_bib68","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1172\/JCI133398","article-title":"Striatal Kir2 K+ channel inhibition mediatesthe antidyskinetic effects of amantadine","volume":"130","author":"Shen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuropharm.2025.110786_bib69","volume":"vol. 197","author":"Sinclaire","year":"2023"},{"key":"10.1016\/j.neuropharm.2025.110786_bib70","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuroscience.2021.06.007","article-title":"Relationships and interactions between ionotropic glutamate receptors and nicotinic receptors in the CNS","volume":"468","author":"Stone","year":"2021","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110786_bib71","doi-asserted-by":"crossref","first-page":"8498","DOI":"10.1523\/ENEURO.0095-15.2015","article-title":"Nicotine modifies corticostriatal plasticity and amphetamine rewarding behaviors in mice","volume":"3","author":"Storey","year":"2016","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2025.110786_bib72","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/mds.30175","article-title":"NLX-112 randomized phase 2A trial: safety, tolerability, anti-dyskinetic, and anti-parkinsonian efficacy","volume":"40","author":"Svenningsson","year":"2025","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110786_bib73","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/mds.22721","article-title":"Advances in environmental epidemiology","volume":"25","author":"Tanner","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110786_bib74","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.neuropharm.2016.02.028","article-title":"Integration of inhibitory and excitatory effects of \u03b17 nicotinic acetylcholine receptor activation in the prelimbic cortex regulates network activity and plasticity","author":"Udakis","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110786_bib75","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","article-title":"Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system","volume":"24","author":"Ungerstedt","year":"1970","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110786_bib76","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2014.01.072","article-title":"The therapeutic promise of positive allosteric modulation of nicotinic receptors","volume":"727","author":"Uteshev","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1073\/pnas.0408305102","article-title":"Regulation of a protein phosphatase Cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum","volume":"102","author":"Valjent","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110786_bib78","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40265-016-0568-1","article-title":"Drug-induced dyskinesia, part 2: treatment of tardive dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2025.110786_bib79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/taap.2000.8896","article-title":"Direct block of inward rectifier potassium channels by nicotine","volume":"164","author":"Wang","year":"2000","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib80","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/mol.111.074302","article-title":"Investigation of the molecular mechanism of the \u03b17 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states","volume":"80","author":"Williams","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib81","first-page":"12428","volume":"vol. 29","author":"Xiao","year":"2009"},{"key":"10.1016\/j.neuropharm.2025.110786_bib82","series-title":"Treatment for Dyskinesia in Parkinson's Disease: a Network","author":"Yan","year":"2025"},{"key":"10.1016\/j.neuropharm.2025.110786_bib83","first-page":"1","article-title":"Multiple cholinergic receptor subtypes coordinate dual modulation of acetylcholine on anterior and posterior paraventricular thalamic neurons","author":"Ye","year":"2024","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110786_bib85","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.113.207639","article-title":"Nicotinic receptor agonists reduce L-DOPA-Induced dyskinesias in a monkey model of Parkinson's disease","volume":"347","author":"Zhang","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110786_bib86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/jpet.114.216283","article-title":"The \u03b17 nicotinic receptor agonist ABT-107 decreases L-dopa-induced dyskinesias in parkinsonian monkeys","volume":"351","author":"Zhang","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110786_bib89","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/neu.10150","article-title":"Cholinergic interneuron characteristics and nicotinic properties in the striatum","volume":"53","author":"Zhou","year":"2002","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110786_bib90","first-page":"8785","volume":"vol. 22","author":"Zoli","year":"2002"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:19:26Z","timestamp":1781191166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":68,"alternative-id":["S0028390825004940"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110786","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of levodopa-induced abnormal involuntary movements (AIMs) using a selective \u03b17 nicotinic positive allosteric modulator","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 University of Hertfordshire. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110786"}}